Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.

Masataro TodaKentaro FujiiAyumi YoshifujiYasushi KondoKazuto ItohKazuhiko SekineTakahide KikuchiMunekazu Ryuzaki

Published in: Clinical and experimental nephrology (2021)

TCZ combined with mPSL pulse therapy improved the survival rate without significant adverse events in critical HD and non-HD patients with COVID-19 by strongly suppressing systemic hyperinflammation.

Keyphrases

combination therapy
blood pressure
end stage renal disease
coronavirus disease
ejection fraction
rheumatoid arthritis
sars cov
newly diagnosed
prognostic factors
stem cells
bone marrow
mesenchymal stem cells
patient reported